Sensei Biotherapeutics Inc (SNSE) - Total Liabilities
Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has total liabilities worth $4.58 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sensei Biotherapeutics Inc (SNSE) cash conversion ratio to assess how effectively this company generates cash.
Sensei Biotherapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Sensei Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check SNSE financial resilience to evaluate the company's liquid asset resilience ratio.
Sensei Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ecomiam SA
PA:ALECO
|
France | €7.48 Million |
|
Greenland Acquisition Corp
NASDAQ:GTEC
|
USA | $53.57 Million |
|
High Peak Royalties Ltd
AU:HPR
|
Australia | AU$1.21 Million |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
India | Rs928.58 Million |
|
Ginting Jaya Energi
JK:WOWS
|
Indonesia | Rp109.07 Billion |
|
M.P.Evans Group
LSE:MPE
|
UK | GBX60.30 Million |
|
Clemondo Group AB (publ)
ST:CLEM
|
Sweden | Skr101.25 Million |
|
GULLBERG+JANSSON AB
F:9D7
|
Germany | €121.61 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Sensei Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Sensei Biotherapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sensei Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sensei Biotherapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Sensei Biotherapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.97 Million | -26.42% |
| 2023-12-31 | $9.48 Million | -36.67% |
| 2022-12-31 | $14.97 Million | +123.00% |
| 2021-12-31 | $6.71 Million | +21.26% |
| 2020-12-31 | $5.54 Million | -92.08% |
| 2019-12-31 | $69.88 Million | +26.29% |
| 2018-12-31 | $55.33 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also off… Read more